Search
Gallium nitrate
go.drugbank.com/drugs/DB05260ApprovedInvestigationalGallium nitrate is a nitrate salt of [DB14524], a heavy metal that has been used as a diagnostic agent.[A260816] Gallium nitrate is reported to possess antiresorptive and hypocalcemic effects on bone. … [A17097] GANITE, a product of gallium nitrate previously used to treat cancer-related hypercalcemia, was discontinued from marketing in the US for reasons other than safety or effectiveness.
Clove oil
go.drugbank.com/drugs/DB11338ApprovedNutraceuticalThe FDA categorizes clove oil as generally recognized as safe (GRAS) for use in dental cement or as a food additive [F108]. … Traditionally, it has been used as a flavouring spice in foods, or as a fragrance. It is also found in topical analgesics. Clove oil has shown to exert some antimicrobial activities.
Efbemalenograstim alfa
go.drugbank.com/drugs/DB18704ApprovedInvestigational[L48852,A262167] As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and eventually neutrophils, the administration of recombinant G-CSF like efbemalenograstim … This approval was contingent on positive results observed in two pivotal Phase 3 Studies GC-627-04 and GC-627-05 in the US and Europe respectively.[L48887]
Vilanterol
go.drugbank.com/drugs/DB09082ApprovedInvestigational[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and … [A259961] Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds
Cemiplimab
go.drugbank.com/drugs/DB14707ApprovedInvestigational[L39804] Cemiplimab was first approved by the FDA on September 28, 2018, as the first FDA-approved treatment for advanced cutaneous squamous cell carcinoma (CSCC).
Miglustat
go.drugbank.com/drugs/DB00419ApprovedInvestigationalMiglustat was first developed as an anti-HIV agent in the 1990s.
Lofexidine
go.drugbank.com/drugs/DB04948ApprovedInvestigational[A33084] It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. … [T210] Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine.
Neratinib
go.drugbank.com/drugs/DB11828ApprovedInvestigationalNeratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer.
Oliceridine
go.drugbank.com/drugs/DB14881ApprovedInvestigational[A218031, A218046] However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors such as those involving β-arrestin … effects such as constipation and respiratory depression.
Spironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigationalIt binds to mineralocorticoid receptors and functions as aldosterone antagonists.[A178192] It promotes sodium and water excretion and potassium retention.